Test Price
2,600 AED✅ Home Collection Available
Next‑Generation Sequencing (NGS) Alzheimer’s Disease Genetic Test in UAE | 2,600 AED | DHA Registered Lab
Executive Summary & Core Metrics
DHA‑Registered Genomic Service provided by DNA Labs UAE (DHA License: 1143)
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139) and dual‑platform NGS + Sanger validation.
- Premium Logistics: Hospital‑grade home collection with ISO‑certified cold‑chain transport (8 AM – 11 PM), VIP mobile phlebotomy included.
- Clinical Guidance: Post‑test telephonic clinical correlation session with a DHA‑licensed genetic counsellor to interpret actionable variants.
- Insurance & Billing: Direct insurance verification via WhatsApp +971 54 548 8731; approved by major UAE networks.
Test Overview & Methodology
This next‑generation sequencing panel screens for pathogenic variants in genes linked to early‑onset and familial Alzheimer’s disease (APP, PSEN1, PSEN2), as well as the APOE susceptibility genotype, using a clinically validated NGS workflow with Sanger confirmation of all reportable findings. Results are delivered in a structured clinical report within 40 working days, fully compliant with DHA genomic reporting standards.
| Feature | Our NGS Panel (DHA‑Registered) | Closest Alternative (Standard APOE Genotyping) |
|---|---|---|
| Precision | NGS with Sanger validation; >99.9% analytical sensitivity & specificity | Genotyping array only; limited to APOE ε2/ε3/ε4 alleles |
| Methodology | Whole‑exome capture + targeted Alzheimer’s gene panel; dual‑platform confirmation | Single‑nucleotide polymorphism (SNP) genotyping with no sequence‑level variant detection |
| Turnaround / Scope | 40 working days; covers all known Alzheimer’s‑associated genes | 5–7 days; risk stratification based on APOE alone |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I emphasize that genetic susceptibility testing for Alzheimer’s disease provides probabilistic risk assessment, not a definitive diagnosis. The identification of variants in APP, PSEN1, PSEN2, or APOE must be rigorously contextualized within the patient’s comprehensive neurological history and pedigree analysis. A positive finding elevates risk but does not equate to disease manifestation, necessitating informed, non-directive genetic counselling.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Advisory & Safety Protocol
Medication & Therapeutic Guidance
Do not discontinue or adjust any prescribed medication (including cholinesterase inhibitors, memantine, or anti‑depressants) based solely on this test result. All therapeutic changes must be directed by your neurologist or psychiatrist.
Exclusion Criteria & Emergency Red Flags
Sample & Clinical Contraindications
- Inadequate sample volume (< 2 mL total) or clotted/highly hemolyzed specimens.
- Incomplete or unverified Whole Exome Sequencing Consent Form (Form 37).
- Recent whole‑blood transfusion (< 4 weeks) – may introduce donor DNA.
- Emergency Red Flags: If you experience sudden confusion, loss of consciousness, or psychosis‑like symptoms, seek immediate emergency care and inform the attending physician about this pending genetic test.
Patient FAQ & Clinical Guidance
1. What exactly does this Alzheimer’s NGS panel detect?
This panel analyzes multiple Alzheimer’s‑related genes using next‑generation sequencing to identify pathogenic variants that can influence disease risk. It covers the major causative genes (APP, PSEN1, PSEN2) and the APOE risk modifier, providing a comprehensive genomic risk profile.
2. Is a home blood collection safe and DHA‑compliant?
Yes. Our DHA‑licensed phlebotomists utilize hospital‑grade, ISO‑certified cold‑chain logistics to ensure specimen integrity and full regulatory compliance. VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection is available daily from 8 AM to 11 PM.
3. Can I share my result directly with a specialist abroad?
Yes. Our structured XML/PDF report follows international medical genetics standards (HGVS nomenclature) for seamless sharing with global consultants, ensuring interoperability and clinical utility across healthcare systems.
UAE Regulatory & Data Privacy Adherence
The regulatory framework governing this service strictly adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols are validated under Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE operates under DHA Facility License Number 1143, ensuring all genomic workflows and genetic counselling services meet the stringent quality standards of the Dubai Health Authority. Our ISO 9001:2015 Certification (INT/EGQ/2509DA/3139) guarantees continuous quality management across all laboratory processes.
Clinical & Logistical Metadata
| Test Name | Next‑Generation Sequencing (NGS) Alzheimer’s Disease Genetic Test |
| Price (AED) | 2,600 AED |
| Turnaround Time | 40 Working Days |
| Sample Type / Matrix | Peripheral Whole Blood (VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection Available) |
| Methodology Used | Whole‑Exome Capture + Targeted Alzheimer’s Gene Panel with Sanger Confirmation |
| ICD-10-CM Code | G30.9, Z13.858 |
| LOINC Code | 101260-9 |
| DHA Facility License & Lab Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians